InMed Pharmaceuticals Inc. (MTRI) stock
MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/30
$17.50−2.37 (-11.93%)
Close on Nov 17, 2026Market cap $96.14MP/E –Yield –
InMed Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
InMed Pharmaceuticals's gross margin for the twelve months ending Dec 31, 2025 was 29.7%. For fiscal 2025 it was 34.5%, against 23.9% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 34.5% | +10.6 |
| FY2024 | Jun 30, 2024 | 23.9% | −10.0 |
| FY2023 | Jun 30, 2023 | 33.9% | −16.0 |
| FY2022 | Jun 30, 2022 | 49.9% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | 22.5% | −19.0 |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | 36.0% | −3.0 |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | 44.2% | +7.9 |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | 13.9% | −10.8 |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | 41.5% | +15.3 |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | 39.0% | +36.7 |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | 36.3% | −31.6 |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | 24.7% | +6.1 |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | 26.1% | −1.8 |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | 2.4% | +155.4 |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | 68.0% | +19.4 |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | 18.6% | −40.3 |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | 27.9% | −14.2 |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -153.1% | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | 48.5% | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | 58.9% | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | 42.1% | – |
See a number that looks wrong?